Study Objective: To evaluate the safety and efficacy, by measuring antifactor Xa levels, of enoxaparin 1 mg/kg subcutaneously once every 24 hours in patients with severe renal failure.
Design: Prospective study.
Setting: Emergency, internal medicine, geriatrics, and cardiology departments of a medical center in Israel.
Patients: Nineteen patients with stage 4 or 5 chronic kidney disease who required full anticoagulation.
Intervention: Patients received enoxaparin 1 mg/kg subcutaneously every 24 hours for 2 or more days, as determined by a treating physician.
Measurements And Main Results: Data on patients' demographic and clinical characteristics were collected. Blood samples for peak and trough antifactor Xa levels were obtained during the enoxaparin treatment period. Of the 19 study patients, 14 (74%) had peak antifactor Xa levels within the recommended range for full anticoagulation of 0.5-1.0 U/ml after their first enoxaparin dose; no concentration exceeded 1.0 U/ml. The mean peak antifactor Xa level was not significantly different after the first enoxaparin dose compared with the second and third doses. The mean +/- SD trough antifactor Xa level, thought to be an indicator of drug accumulation, was 0.12 +/- 0.12 U/ml; its clinical significance and target range are still unknown. No major bleeding events were noted.
Conclusion: Enoxaparin 1 mg/kg once every 24 hours in patients with stage 4 or 5 chronic kidney disease who required full anticoagulation was safe, and this dose did not exceed recommended concentrations. The significance of enoxaparin trough levels remains unclear and should be investigated in future studies. Other dosing regimens of enoxaparin for specific patient populations should also be assessed for safety and efficacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1592/phco.27.10.1347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concordance and discordance of anticoagulation assays in children supported by ECMO: The truth is out there.
Perfusion
December 2024
Department of Pediatrics, Section of Pediatric Critical Care Medicine, Yale, New Haven, CT, USA.
Introduction: Extracorporeal membrane oxygenation (ECMO) provides critical support to patients in severe cardiac and respiratory failure, but it requires anticoagulation to prevent complications like bleeding and thrombosis. Heparin, the primary anticoagulant utilized, is monitored by activated partial thromboplastin time (aPTT) and anti-Factor Xa (AntiXa) levels. Discordance between the two assays complicates its titration and the impact on patient outcomes is not well-established.
View Article and Find Full Text PDFBalancing safety and efficacy of low-molecular-weight heparins in neonates: a systematic review.
Res Pract Thromb Haemost
October 2024
Department of Pediatrics-Hematology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
The rising incidence of venous thromboembolism (VTE) in neonates has led to increased use of low-molecular-weight heparins (LMWHs), but optimal dosages remain uncertain. A serious adverse effect of LMWHs is major bleeding. Given the vulnerability of neonates to major bleeding, we aimed to review therapeutic and prophylactic LMWH dosages to achieve target anti-factor Xa ranges of 0.
View Article and Find Full Text PDFPregnant Woman in Outcomes with Prosthetic Heart Valves.
J Cardiovasc Dev Dis
November 2024
Almazov National Medical Research Centre, St. Petersburg 197341, Russia.
Article Synopsis
- This study investigated thrombotic and hemorrhagic complications during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV), covering 88 pregnancies from January 2011 to December 2022.
- Of the pregnancies, 79 resulted in live births, with higher miscarriage rates in the mechanical valve prosthesis (MVP) group compared to the biological valve prosthesis (BVP) group, alongside notable thrombotic complications predominantly in the MVP group.
- While effective anti-factor Xa activity control was noted to reduce thrombotic events, the study highlighted a concerning rate of postpartum hemorrhagic complications, suggesting a need for revising anticoagulant therapy protocols.
Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.
Int Immunopharmacol
December 2024
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Medical Technology and Engineering College of Fujian Medical University, Fuzhou, Fujian, China; Key Laboratory of Clinical Laboratory Technology for Precision Medicine (Fujian Medical University), Fujian Province University, Fuzhou, China. Electronic address:
Article Synopsis
- The study investigates the formation of anti-factor VIII (FVIII) inhibitors in hemophilia A patients and the role of the chemokine CXCL13 in this process.
- It was found that CXCL13 levels were significantly elevated in hemophilia A patients with inhibitors compared to those without, suggesting a link between CXCL13 and inhibitor development.
- The research indicates that targeting CXCL13 could be a promising therapeutic strategy for managing FVIII inhibitors in hemophilia A patients.
Evaluating chemical venous thromboembolism prophylaxis in trauma patients at a single Australian center.
J Trauma Inj
September 2024
Intensive Care Unit, Canberra Hospital, Garran, ACT, Australia.
Purpose: Trauma patients are at an elevated risk of developing venous thromboembolism (VTE), with the subsequent mortality in patients requiring intensive care unit admission ranging from 25% to 38%. There remains significant variability in clinical practice related to VTE prophylaxis in trauma patients due to the frequent presence of contraindications impacting the timing and consistency of application. This study aimed to assess the effectiveness of the current practice of chemical VTE prophylaxis in trauma patients at a single Australian center.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!